In addition, a study demonstrated that the malignant phenotype of HCC is associated with higher expression of the NRF2 target gene glutamate–cysteine ligase catalytic subunit (GCLC), and that its level can predict clinical outcome after resection, even in early-stage HCC [14]. The gene discussed is GCLC; the disease is hepatocellular carcinoma.